Alkermes Plc
ALKS26.500USD
-0.050-0.19%
Market hours （ET）Quotes delayed by 15 min
4.37BMarket Cap
12.40P/E TTM
More Details of Alkermes Plc Company
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Company Info
Ticker SymbolALKS
Company nameAlkermes Plc
IPO dateJul 16, 1991
CEOMr. Richard F. Pops
Number of employees1800
Security typeOrdinary Share
Fiscal year-endJul 16
AddressConnaught House
CityDUBLIN
Stock exchangeNASDAQ Global Select Consolidated
CountryIreland
Postal codeD04 C5Y6
Phone35317728000
Websitehttps://www.alkermes.com/
Ticker SymbolALKS
IPO dateJul 16, 1991
CEOMr. Richard F. Pops
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
204.25K
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.74K
--
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Dr. Cato T. Laurencin, M.D., Ph.D.
Dr. Cato T. Laurencin, M.D., Ph.D.
Independent Director
Independent Director
29.10K
+26.46%
Dr. Christopher I. Wright, M.D., Ph.D.
Dr. Christopher I. Wright, M.D., Ph.D.
Independent Director
Independent Director
23.01K
+12.23%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
10.71K
+131.91%
Dr. Nancy L. Snyderman, M.D.
Dr. Nancy L. Snyderman, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard F. Pops
Mr. Richard F. Pops
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.29M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
204.25K
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
103.74K
+3.84%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
77.74K
--
Mr. Brian P. Mckeon
Mr. Brian P. Mckeon
Independent Director
Independent Director
43.87K
+16.12%
Mr. Frank Anders (Andy) Wilson, CPA
Mr. Frank Anders (Andy) Wilson, CPA
Lead Independent Director
Lead Independent Director
31.08K
+24.36%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
VIVITROL
101.00M
32.95%
ARISTADA
73.47M
23.97%
LYBALVI
70.02M
22.84%
Royalty Revenue - VUMERITY
21.86M
7.13%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
17.75M
5.79%
Other
22.41M
7.31%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
VIVITROL
101.00M
32.95%
ARISTADA
73.47M
23.97%
LYBALVI
70.02M
22.84%
Royalty Revenue - VUMERITY
21.86M
7.13%
Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA
17.75M
5.79%
Other
22.41M
7.31%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.53%
The Vanguard Group, Inc.
11.00%
T. Rowe Price Associates, Inc.
7.04%
State Street Global Advisors (US)
4.86%
RTW Investments L.P.
4.17%
Other
58.40%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.53%
The Vanguard Group, Inc.
11.00%
T. Rowe Price Associates, Inc.
7.04%
State Street Global Advisors (US)
4.86%
RTW Investments L.P.
4.17%
Other
58.40%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.22%
Investment Advisor/Hedge Fund
30.61%
Hedge Fund
12.64%
Research Firm
2.77%
Individual Investor
1.66%
Pension Fund
1.62%
Sovereign Wealth Fund
1.24%
Bank and Trust
0.42%
Private Equity
0.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
769
179.19M
108.55%
-26.81M
2025Q1
781
180.42M
109.41%
-27.12M
2024Q4
750
175.04M
107.61%
-39.68M
2024Q3
727
186.93M
115.42%
-33.14M
2024Q2
708
187.79M
113.20%
-24.77M
2024Q1
682
184.21M
108.96%
-28.40M
2023Q4
653
184.12M
110.36%
-5.13M
2023Q3
620
171.53M
102.92%
-4.71M
2023Q2
610
167.10M
100.38%
-17.86M
2023Q1
604
167.47M
100.88%
-20.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
23.98M
14.54%
-541.92K
-2.21%
Mar 31, 2025
The Vanguard Group, Inc.
18.16M
11.01%
-283.51K
-1.54%
Mar 31, 2025
T. Rowe Price Associates, Inc.
11.62M
7.05%
-472.94K
-3.91%
Mar 31, 2025
State Street Global Advisors (US)
8.02M
4.87%
-792.30K
-8.99%
Mar 31, 2025
RTW Investments L.P.
6.88M
4.17%
-673.14K
-8.91%
Mar 31, 2025
Renaissance Technologies LLC
5.74M
3.48%
+260.10K
+4.75%
Mar 31, 2025
Baker Bros. Advisors LP
4.48M
2.72%
+301.53K
+7.21%
Mar 31, 2025
JP Morgan Asset Management
4.13M
2.5%
+3.88M
+1560.15%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.94M
2.39%
+121.05K
+3.17%
Mar 31, 2025
American Century Investment Management, Inc.
3.47M
2.1%
+14.97K
+0.43%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
6.14%
iShares Neuroscience and Healthcare ETF
3.95%
Invesco S&P SmallCap Health Care ETF
3.37%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
ALPS Medical Breakthroughs ETF
3.19%
Tema Neuroscience and Mental Health ETF
1.88%
Knowledge Leaders Developed World ETF
1.68%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.4%
Invesco S&P SmallCap Quality ETF
1.34%
Janus Henderson Small Cap Growth Alpha ETF
1.25%
View more
AdvisorShares Psychedelics ETF
Proportion6.14%
iShares Neuroscience and Healthcare ETF
Proportion3.95%
Invesco S&P SmallCap Health Care ETF
Proportion3.37%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.33%
ALPS Medical Breakthroughs ETF
Proportion3.19%
Tema Neuroscience and Mental Health ETF
Proportion1.88%
Knowledge Leaders Developed World ETF
Proportion1.68%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.4%
Invesco S&P SmallCap Quality ETF
Proportion1.34%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.25%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
